Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly CEO Prescribes Greater Transparency, Coverage For Healthcare System

Executive Summary

One way to control rising healthcare costs would be through greater pricing transparency, including for pharmaceuticals, Lilly CEO Sidney Taurel suggested

You may also be interested in...

Rx Prices Reflect “Anticipated Income,” Not R&D Costs, Pfizer CEO Says

Pharmaceutical pricing decisions are based on "anticipated income" rather than achieving a return on R&D costs, Pfizer CEO Hank McKinnell writes in his recently published book A Call To Action: Taking Back Healthcare for Future Generations

PhRMA Marketing Code Prohibits Personal Gifts To Physician

The Pharmaceutical Research & Manufacturers of America marketing code includes an explicit prohibition on "items intended for the personal benefit of healthcare professionals.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts